Clinical Trial Update: PXD101 and 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating PXD101 in combination with 17-N-allylamino-17-demethoxygeldanamycin for metastatic or unresectable solid tumors or lymphoma has been …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anaplastic Large Cell Lymphoma
• Burkitt Lymphoma
• Diffuse Large B-cell Lymphoma
• Extranodal Nk T-cell Lymphoma Nasal Type
• Follicular Lymphoma
• Hodgkin Lymphoma
• Mantle Cell Lymphoma
• Marginal Zone Lymphoma

Drugs mentioned

• 17-N-Allylamino-17-Demethoxygeldanamycin (tanespimycin)
• PXD101

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma | Phase 1 | Status: TERMINATED